Clinical Trials Logo

Filter by:
NCT ID: NCT01197534 Completed - Clinical trials for Rheumatoid Arthritis

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.

OSKIRA - 2
Start date: September 2010
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the effectiveness of two dosing regimens of fostamatinib compared to placebo, in patients with rheumatoid arthritis (RA) who are taking disease modifying anti-rheumatic drug (DMARD) but not responding. The study will last for 1 year.

NCT ID: NCT01197508 Completed - Clinical trials for Major Depressive Disorder

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.

Start date: September 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like a medicine tablet or capsule, but contains no active medicine) is safe and effective when taken together with another antidepressant.

NCT ID: NCT01196156 Completed - Clinical trials for Infant, Small for Gestational Age

Follow-up to Adult Height of a Cohort of Subjects Born Small for the Gestational Age and Treated With Growth Hormone

SGA
Start date: September 30, 2005
Phase:
Study type: Observational

This non-interventional study for prospective follow up of a cohort of 220 subjects born small for gestational age (SGA) is planned for the purpose of finding out if normalisation of adult height is associated or not with metabolic alterations and if true, their magnitude and relevance as well as to detect warnings throughout the treatment period that may be useful for prevention or therapy. This study would help in answering the question if the SGA and growth hormone (GH) association results in insulin resistance and if affirmative, who develops it as well as its impact on other metabolic parameters that precedes type 2 diabetes.

NCT ID: NCT01196052 Completed - Breast Cancer Clinical Trials

A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer

Start date: October 2010
Phase: Phase 2
Study type: Interventional

This single-arm open-label study assessed the safety, feasibility, and efficacy of trastuzumab emtansine (T-DM1) after the completion of anthracycline-based adjuvant/neoadjuvant chemotherapy in patients with early HER2-positive breast cancer. Patients received T-DM1 3.6 mg/kg intravenously on Day 1 of each 3-week cycle, for up to 17 cycles.

NCT ID: NCT01195766 Completed - Hodgkin Disease Clinical Trials

Study of Ofatumumab and ESHAP for the Treatment of Hodgkin's Lymphoma

Start date: July 2010
Phase: Phase 2
Study type: Interventional

The aim of this study is to analyze the efficacy of O-ESHAP treatment for Hodgkin's lymphome patients that have a first line chemotherapy treatment failure due to refractoriness, partial response or relapsed. In the same way, mortality, global survival and free-progression survival after O-ESHAP treatment and TAPH will also analyzed.

NCT ID: NCT01195194 Completed - Clinical trials for Disorder Related to Renal Transplantation

Selection of Immunosuppression in Kidney Transplant Recipients Depending on Pre-transplant Donor-specific T-cell Reactivity.

SIRES
Start date: March 2008
Phase: Phase 4
Study type: Interventional

The objective is to assess if low pre-transplantation donor specific T-cell reactive patients measured by Enzyme-linked immunosorbent spot (ELISPOT)assay can be safely managed with Calcineurin inhibitor(CNI)-free Sirolimus(SRL)-based immunosuppression.

NCT ID: NCT01194973 Completed - Clinical trials for Atypical Hemolytic-Uremic Syndrome

An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome

Start date: July 2010
Phase: Phase 2
Study type: Interventional

The record Primary purpose is to assess the efficacy of eculizumab in adult patients with aHUS to control TMA as characterized by thrombocytopenia, hemolysis and renal impairment.

NCT ID: NCT01194791 Completed - Clinical trials for Primary Systemic Amyloidosis

Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed

LENDEXAL
Start date: October 2010
Phase: Phase 2
Study type: Interventional

Primary outcome measure: - Hematologic response rate to the association of Lenalidomide, Cyclophosphamide and Dexamethasone. Secondary outcome measures: - Organ response rate. - Predictors of response (cardiac biomarkers, serum free light chains). - Toxicity - Safety (type, frequency, severity and relationship of adverse events to the study drug). - Duration of response. - Time to progression. - Overall survival

NCT ID: NCT01194596 Completed - Smoking Cessation Clinical Trials

Effectiveness of Smoking Cessation Advice Combined With Spirometric Results in Adult Smokers (ESPITAP)

ESPITAP
Start date: June 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the effectiveness of the spirometric results information advice about the smoking habit the investigators designed an intervention trial in primary care. Hypothesis: In adult smokers, smoking cessation advice combined with a discussion of the spirometric tests on the part of the practitioner achieves a higher rate of tobacco reduction and abandonment than just smoking cessation advice. Expected results: In adult smokers, a detailed discussion of the results yielded by spirometry tests together with brief smoking cessation advice on the part of the primary care practitioner can facilitate tobacco reduction and abandonment.

NCT ID: NCT01194570 Completed - Clinical trials for Multiple Sclerosis, Primary Progressive

A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

Start date: March 2, 2011
Phase: Phase 3
Study type: Interventional

This randomized, parallel group, double-blind, placebo controlled study will evaluate the efficacy and safety of ocrelizumab in participants with primary progressive multiple sclerosis. Eligible participants will be randomized 2 : 1 to receive either ocrelizumab or placebo.